Core view
The pharmaceutical sector has gradually bottomed and rebounded, and the time point for strategic allocation has come. This week, all A-Shares rose 1.62%, CSI 300 rose 2.43%, and the biomedical sector as a whole fell 0.15%, which was weaker than the overall market. In terms of molecular section, chemical pharmaceuticals fell by 1.26%, biological products fell by 2.88%, medical services rose by 1.60%, medical devices rose by 1.11%, pharmaceutical business fell by 2.63% and traditional Chinese medicine rose by 1.13%. The “14th five year plan” of traditional Chinese medicine has been released, and the inheritance and development of traditional Chinese medicine has become the main theme. On March 29, the general office of the State Council issued the “14th five year plan for the development of traditional Chinese medicine”, which is the first Five-Year Plan for traditional Chinese Medicine issued in the name of the general office of the State Council. The setting of indicators more reflects the requirements for the high-quality development of traditional Chinese medicine in the new era. In the goals set in the 14th five year plan for the development of traditional Chinese medicine, a number of per capita indicators have increased significantly. The plan also defines ten main tasks, involving all aspects of TCM diagnosis and treatment, and highlights the characteristic advantages of TCM in health services, which are reflected in disease prevention (such as TCM Prevention formula involved in covid-19 Treatment Guide), advantageous specialties (such as cardio cerebrovascular, skin, rehabilitation, etc.). The policy boom cycle has come, and we are optimistic about three types of traditional Chinese medicine targets: 1) capacity expansion subdivision track: we are optimistic about traditional Chinese medicine formula granule manufacturers with upstream planting (breeding) resources, high standards and early layout. Recommended purchase: Chinese traditional medicine; 2) High quality enterprises that return to the drug attribute, have definite product efficacy and have the ability to continuously produce new products: excellent traditional Chinese medicine enterprises whose products have been fully verified by evidence-based medicine and recognized by doctors. Recommended purchase: Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) ; 3) Target of consumption attribute: OTC leading enterprises that are optimistic about products, occupy consumers’ minds, have a stable pattern and have a good brand image under long-term accumulation. Recommended purchase: China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) .
Antigen detection is widely used in Shanghai and has become an important means of personnel screening and diversion. As of April 3, 24 covid-19 antigen detection products have been approved for listing, including 17 colloidal gold methods, 4 latex methods and 3 fluorescence immunochromatography methods. There are 11 listed companies among the 24 manufacturers. At present, the production capacity of antigen detection products in China has increased rapidly, which is conducive to China’s epidemic prevention. As a super large-scale city, the use of antigen detection products in Shanghai is conducive to early detection and rapid disposal of infectious sources, interception and interdiction of the spread of the epidemic. The city wide antigen detection in Shanghai and the requirements for negative antigen detection in specific populations and situations will point out the direction for the follow-up application and improve the attention to covid-19 antigen detection.
Risk tips: the risk of repeated epidemic, the risk of exceeding the expected cost of medical insurance control, and the risk of centralized drug consumption
